PEAK6 Investments’s Royalty Pharma RPRX Stock Holding History

PEAK6 Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,600	Closed	-$206K	–	4754
2023 Q3	$206K	Sell	7,600 -1,500	-16%	-$44.6K	﹤0.01%	3050
2023 Q2	$280K	Sell	9,100 -16,000	-64%	-$542K	﹤0.01%	2649
2023 Q1	$904K	Sell	25,100 -4,900	-16%	-$182K	﹤0.01%	1929
2022 Q4	$1.19M	Sell	30,000 -30,900	-51%	-$1.29M	0.01%	1781
2022 Q3	$2.45M	Sell	60,900 -9,100	-13%	-$389K	0.01%	1379
2022 Q2	$2.84M	Buy	+70,000	New	+$2.87M	0.01%	1921

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PEAK6 Investments's RPRX Position: Q1 2023 in Review

PEAK6 Investments sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 4,238 shares — an estimated $157K sold.

PEAK6 Investments first reported a position in RPRX in Q4 2022 and held it in 1 quarter. The position peaked at $167K in Q4 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

PEAK6 Investments reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
PEAK6 Investments sold 4,238 Royalty Pharma shares in Q1 2023, an estimated $157K.
PEAK6 Investments first reported a position in Royalty Pharma in Q4 2022 and held it in 1 quarter.
PEAK6 Investments's Royalty Pharma position peaked at $167K in Q4 2022.
335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on PEAK6 Investments's 13F filing for Q1 2023, filed 12 May 2023.